| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA937961 | B | Activity of HCV 1a NS3-4A protease R155K mutant | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 2. | ALA937962 | B | Activity of HCV 1a NS3-4A protease R155T mutant | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 3. | ALA937963 | B | Activity of HCV 1a NS3-4A protease R155S mutant | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 4. | ALA1000338 | B | Inhibition of HCV 1a NS3-4A R155K mutant protease after 60 mins | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 5. | ALA1000339 | B | Inhibition of HCV 1a NS3-4A R155T mutant protease after 60 mins | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 6. | ALA1000340 | B | Inhibition of HCV 1a NS3-4A protease R155S mutant after 60 mins | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 7. | ALA1000341 | B | Inhibition of HCV 1a NS3-4A R155I mutant protease after 60 mins | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 8. | ALA1058780 | B | Inhibition of HCV genotype 1a NS3 protease V36M mutant expressed in Escherichia coli BL21 (DE3) | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 9. | ALA1058781 | B | Inhibition of HCV genotype 1a NS3 protease V36L mutant expressed in Escherichia coli BL21 (DE3) | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 10. | ALA1058782 | B | Inhibition of HCV genotype 1a NS3 protease V36M/R155K double mutant expressed in Escherichia coli BL21 (DE3) | Hepatitis C virus subtype 1a | 1 | assay format | Scientific Literature | ||
| 11. | ALA1177150 | B | Inhibition of HCV NS3 protease D168V mutant by FRET assay | Hepatitis C virus | 6 | assay format | Scientific Literature | ||
| 12. | ALA1227201 | B | Inhibition of HCV NS3 protease D168V mutant by FRET assay | Hepatitis C virus | 5 | assay format | Scientific Literature | ||
| 13. | ALA3124301 | B | Inhibition of Hepatitis C virus genotype 1a NS3/4A protease A156T mutant expressed in Escherichia coli BL21 (DE3) cells assessed as substrate cleavage using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]AS-C(5-FAMsp)-NH2 as substrate by plate reader analysis | Hepatitis C virus subtype 1a | 1 | cell-based format | Scientific Literature | ||
| 14. | ALA3128537 | B | Inhibition of Hepatitis C virus genotype 1a full length NS3/2K-NS4A protease R155K mutant using Ac-DED(Edans)EEAbupsi[COO]ASK(Dabcyl)-NH2 as substrate incubated for 10 mins prior to substrate addition by FRET analysis | Hepatitis C virus subtype 1a | 2 | assay format | Scientific Literature | ||
| 15. | ALA3128538 | B | Inhibition of Hepatitis C virus genotype 1a full length NS3/2K-NS4A protease D168V mutant using Ac-DED(Edans)EEAbupsi[COO]ASK(Dabcyl)-NH2 as substrate incubated for 10 mins prior to substrate addition by FRET analysis | Hepatitis C virus subtype 1a | 2 | assay format | Scientific Literature | ||
| 16. | ALA3128539 | B | Inhibition of Hepatitis C virus genotype 1a full length NS3/2K-NS4A protease A156T mutant using Ac-DED(Edans)EEAbupsi[COO]ASK(Dabcyl)-NH2 as substrate incubated for 10 mins prior to substrate addition by FRET analysis | Hepatitis C virus subtype 1a | 2 | assay format | Scientific Literature | ||
| 17. | ALA3131503 | B | Inhibition of full-length HCV NS3 protease D168V mutant | Hepatitis C virus | 5 | assay format | Scientific Literature | ||
| 18. | ALA3888898 | B | FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10× stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13× 5-FAM/QXL™520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 μL of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25° C. with a 0.5 μL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 μL of the FRET substrate and monitored for 120 minutes at λex487/λem514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.). | 3 | single protein format | BindingDB Database | |||
| 19. | ALA3888902 | B | FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10× stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13× 5-FAM/QXL™520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 μL of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 μL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 μL of the FRET substrate and monitored for 60-90 minutes at λex485/λem520 in a Synergy4 plate reader from BioTek (Winooski, Vt.). | 4 | single protein format | BindingDB Database | |||
| 20. | ALA4371146 | B | Inhibition of HCV NS3 protease | Hepatitis C virus | 3 | single protein format | Scientific Literature |
The page will load shortly, Thanks for your patience!